The Food and Drug Administration (FDA) has approved a new presentation of Selarsdi ™ (ustekinumab-aekn), a biosimilar to Stelara ® (ustekinumab), expanding the product’s indications to include ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

T helper 17 (Th17) cells generate the pro-inflammatory cytokine interleukin-17 (IL17/IL17A). IL17 has been a target for a variety of therapeutic monoclonal antibodies and inhibitors to treat ...

Soquelitinib (formerly CPI-818) is an investigational small molecule drug given orally designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase), an enzyme that is expressed ...

The interleukin-6 (IL-6) inhibitors market is poised for significant growth, with a projected compound annual growth rate ...

Interleukin-2 (IL-2) is a pluripotent cytokine that regulates the immune system’s response. The IL-2 receptor (IL-2R) is a heterotrimeric protein that binds to IL-2 and reacts to it on the ...

Participants were broken into two cohorts. The first cohort received one of three doses of PCRX-201. The second cohort received concurrent pretreatment with an intraarticular corticosteroid ...

A team of bioengineers has developed a mathematical model that clarifies why interleukin-12 (IL-12) -- a potent immune-boosting protein that holds promise for cancer treatment -- loses effectiveness ...

Medically reviewed by Mary Choy, PharmD Biologics work by targeting proteins that cause inflammation in ulcerative colitis.

A recent study published in Progress in Neuropsychopharmacology & Biological Psychiatry suggests that cannabidiol (commonly ...

GNSC-001 is an investigational, adeno-associated virus gene therapy expressing an optimized form of interleukin-1 receptor antagonist (IL-1Ra), a protein that blocks interleukin-1 (IL-1) signaling. IL ...